

Product Datasheet

Bevurogant

Catalog No. **BP-01933** · CAS **1817773-66-2** · Form **free base** · Physical state **solid** · Color **White to light yellow** · Version **1.0** · Revision **2026-09-03**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target ROR	Research area Inflammation/Immunology; Cancer
----------------------	---

Molecular formula **C₂₆H₂₈N₈O₃S**

Molecular weight **532.6170**

STRUCTURE



DESCRIPTION

Bevurogant (BI 730357) is a retinoid-related orphan receptor-gamma t (RORγt) antagonist. Bevurogant can be used for the research of chronic inflammatory diseases.

BIOLOGICAL ACTIVITY

In Vitro

Bevurogant can target the Th17 cell-associated pathway, potently inhibit P-gp and potentially inhibit BCRP, and is applicable for investigating Th17-mediated inflammatory diseases such as psoriasis.

In Vivo

Bevurogant has a favorable safety and tolerability profile.

SOLUBILITY

Soluble in DMSO 250 mg/mL

REFERENCES

- [1]. BAKONYI J, et, al. Compounds as modulators of ror gamma. US20150291607A1.
- [2]. Choi H, et al. The Effect of BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open-Label, Non-randomized, 2-Period Fixed-Sequence Trial in Healthy Subjects. Clin Pharmacol Drug Dev. 2024 Feb;13(2):197-207.